| 7.17 0.05 (0.7%) | 07-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 8.67 | 1-year : | 9 |
| Resists | First : | 7.43 | Second : | 7.71 |
| Pivot price | 7.27  |
|||
| Supports | First : | 6.98 | Second : | 5.8 |
| MAs | MA(5) : | 7.2 |
MA(20) : | 7.3 |
| MA(100) : | 8.03 |
MA(250) : | 7.44 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2  |
| %K %D | K(14,3) : | 22.8 |
D(3) : | 29 |
| RSI | RSI(14): 39.7 |
|||
| 52-week | High : | 9.07 | Low : | 6.3 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ KMDA ] has closed above bottom band by 30.5%. Bollinger Bands are 27.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7.21 - 7.25 | 7.25 - 7.3 |
| Low: | 6.98 - 7.04 | 7.04 - 7.09 |
| Close: | 7.08 - 7.17 | 7.17 - 7.26 |
Kamada Ltd. is a biopharmaceutical firm focused on developing, manufacturing, and distributing protein therapeutics derived from human plasma. The company operates through two core business areas: its proprietary product segment and its distribution division. Its own manufactured portfolio includes KAMRAB/KEDRAB for rabies prevention, CYTOGAM to prevent cytomegalovirus disease in transplant recipients, WINRHO SDF for immune thrombocytopenic purpura and Rhesus (Rh) isoimmunization, HEPAGAM B for hepatitis B recurrence prevention following liver transplants and for post-exposure prophylaxis, VARIZIG for post-exposure chickenpox prophylaxis, and GLASSIA for intravenous alpha-1 antitrypsin deficiency (AATD). Kamada also produces KamRho (D) for the prophylaxis of hemolytic disease of newborns and immune thrombocytopenic purpura, along with a specific antiserum for Vipera palaestinae and Echis coloratus snake bites. Additionally, the company distributes a wide array of third-party pharmaceutical products, encompassing treatments like BRAMITOB for chronic pulmonary infections, FOSTER for asthma, PROVOCHOLINE for diagnosing bronchial airway hyperactivity, and specialized therapies such as IVIG for immunodeficiency, VARITECT for chickenpox and zoster herpes, and various factors for hemophilia A and B, among numerous others for conditions like hepatitis B, cytomegalovirus, angioedema, Japanese encephalitis, and prostate cancer. Kamada markets its offerings in the United States through strategic partners and internationally via a network of distributors. The company maintains significant collaborations with Takeda Pharmaceuticals Company Limited, PARI GmbH, and Kedrion Biopharma. Established in 1990, Kamada Ltd. is headquartered in Rehovot, Israel.
Mon, 13 Jul 2026
Kamada highlights study results on CYTOGAM in transplants - Investing.com UK
Mon, 13 Jul 2026
Kamada (KMDA) Presents Promising Cytogam Study Results at Global Conference - GuruFocus
Mon, 13 Jul 2026
[6-K] KAMADA LTD Current Report (Foreign Issuer) | KMDA SEC Filing - Form 6-K - Stock Titan
Mon, 13 Jul 2026
Immune drug CYTOGAM tied to better outcomes in high‑risk lung transplant patients - Stock Titan
Fri, 10 Jul 2026
Price to earnings forward of Kamada Ltd. – NASDAQ:KMDA - TradingView
Sun, 28 Jun 2026
Kamada (KMDA) Corporate Presentation Summary - Quartr
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 58 (M) |
| Shares Float | 31 (M) |
| Held by Insiders | 7.1 (%) |
| Held by Institutions | 48.5 (%) |
| Shares Short | 153 (K) |
| Shares Short P.Month | 135 (K) |
| EPS | 0.34 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.5 |
| Profit Margin | 11.2 % |
| Operating Margin | 15.3 % |
| Return on Assets (ttm) | 4.1 % |
| Return on Equity (ttm) | 7.9 % |
| Qtrly Rev. Growth | 2.7 % |
| Gross Profit (p.s.) | 1.29 |
| Sales Per Share | 3.14 |
| EBITDA (p.s.) | 0.67 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 26 (M) |
| Levered Free Cash Flow | 11 (M) |
| PE Ratio | 20.48 |
| PEG Ratio | 0.6 |
| Price to Book value | 1.59 |
| Price to Sales | 2.27 |
| Price to Cash Flow | 16.08 |
| Dividend | 0.25 |
| Forward Dividend | 0 |
| Dividend Yield | 3.4% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|